Paradiso A, Mangia A, Tortora G, Schittulli F, Delena M
ONCOL INST,DIV MED ONCOL,I-70126 BARI,ITALY. ONCOL INST,DIV SURG SENOL,I-70126 BARI,ITALY.
Int J Oncol. 1995 Mar;6(3):563-7. doi: 10.3892/ijo.6.3.563.
The hormone receptor status and proliferative activity characteristics of inflammatory breast cancer (IBC) were studied in a series of 46 patients. ER and PgR were measured by the DCC method and proliferative activity was by the H-3-thymidine autoradiographic labeling index (H-3-Tdr-LI). Tumors were ER and PgR positive in 42% and 38% of cases, respectively, whereas median H-3-Tdr-LI was 3.8%. With regard to clinical aspects, overall survival (OS) was not affected by either ER status (36 cases) or H-3-Tdr-LI value (33 cases). On the contrary, PgR(+) status was able to individualize women with a significantly higher probability of OS (X(2) by long rank test, p=0.03) after 35 months of follow-up. In the subgroup of 14 patients subjected to double biopsy performed before and after administration of primary polychemotherapy, the tumor proliferative activity variations were not related to clinical outcome.
对46例炎性乳腺癌(IBC)患者的激素受体状态和增殖活性特征进行了研究。采用DCC法检测雌激素受体(ER)和孕激素受体(PgR),通过H-3-胸腺嘧啶核苷放射自显影标记指数(H-3-Tdr-LI)检测增殖活性。肿瘤ER和PgR阳性率分别为42%和38%,而H-3-Tdr-LI中位数为3.8%。在临床方面,总体生存期(OS)不受ER状态(36例)或H-3-Tdr-LI值(33例)的影响。相反,在35个月的随访后,PgR(+)状态能够区分出OS概率显著更高的女性(长秩检验X(2),p = 0.03)。在14例接受原发性多药化疗前后进行双重活检的患者亚组中,肿瘤增殖活性变化与临床结果无关。